Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

153.20 -2.07 (-1.33%)
Streaming Delayed Price Updated: 11:13 AM EST, Feb 18, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
71 72 Next >
News headline image
Analysts Cite Improved Investor Sentiment For Gilead, But Warn of Limited Growth at Current Stock Levels ↗
Gilead Sciences' Q2 2024 revenue rose to $6.95B, beating expectations, driven by strong performance in HIV, Liver Disease, and Oncology. Adjusted EPS surged to $2.01, surpassing estimates, supported by... 
Via Benzinga
News headline image
Wall Street Momentum Stalls After Thursday's Rally, Palantir Jumps To 3-Year Highs, Bonds Rally: What's Driving Markets Friday? ↗
After a blistering Thursday that saw the S&P 500 close with its best session in nearly two years — up 2.3% — Wall Street’s price action turned sluggish on a Friday lacking market-moving economic... 
Via Benzinga
News headline image
Gilead Sciences (GILD) Q2 2024 Earnings Call Transcript ↗
GILD earnings call for the period ending June 30, 2024. 
Via The Motley Fool
Topics Earnings
News headline image
Gilead Eyes A Breakout After Second-Quarter Sales, Earnings Beat ↗
The company retained its full-year outlook for product sales. 
Via Investor's Business Daily
News headline image
$1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
Gilead Sciences's Options Frenzy: What You Need to Know ↗
 
Via Benzinga
News headline image
$100 Invested In Gilead Sciences 20 Years Ago Would Be Worth This Much Today ↗
 
Via Benzinga
News headline image
GILD Stock Earnings: Gilead Sciences Beats EPS, Beats Revenue for Q2 2024 ↗
GILD stock results show that Gilead Sciences beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Gilead Sciences Announces Second Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Wall Street Set For Uneventful Start Ahead Of Jobless Claim Data, VIX Rises: Strategist Says Market May Remain Vulnerable Until... ↗
U.S. stocks are set for a mixed start on Thursday as concerns regarding the economy and incremental yen carry trade unwinding remain an undercurrent. Traders may be keen to receive the jobless claims... 
Via Benzinga
Topics Economy Stocks
News headline image
This Is What Whales Are Betting On Gilead Sciences ↗
 
Via Benzinga
News headline image
Breaking Down Gilead Sciences: 10 Analysts Share Their Views ↗
 
Via Benzinga
News headline image
Wall Street Rallies As Economic Concerns Recede, Tech Flexes Its Muscles, Semiconductors Soar: What's Driving Markets Thursday? ↗
Investor risk sentiment is showing greater conviction on Thursday, with all indices and major stock sectors in the green, after Wall Street failed to hold onto opening gains and closed in the red the... 
Via Benzinga
News headline image
Four Stocks To Watch This Week - Monday, August 5 ↗
The unease we've been mentioning over the past several weeks has borne bearish fruit in the last two weeks. The good news is that stocks are correcting across the board, which means they will... 
Via Talk Markets
News headline image
2 Unstoppable Dividend Stocks to Buy if There's a Stock Market Sell-Off ↗
Dividend stocks are great; cheap dividend stocks are better. 
Via The Motley Fool
News headline image
Q3’s Rising Stars: 3 Nasdaq Stocks for Your Must-Watch List ↗
Traders are rushing out of overvalued and overhyped Nasdaq stocks, making it a great time to rotate into these Nasdaq stocks to watch. 
Via InvestorPlace
News headline image
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet ↗
The Stock Whisper Index provides a weekly list of five stocks that are seeing above-average interest from readers. 
Via Benzinga
News headline image
The Top 3 Biotech Stocks to Buy Now Summer 2024 ↗
These biotech stocks are well-positioned to generate high returns for investors due to their significant growth prospects. 
Via InvestorPlace
News headline image
Kazia Therapeutics Stock: Is KZIA a Buyout Candidate in the Making? ↗
Kazia Therapeutics stock soared after positive clinical trials, which raises its profile amongst pharmas looking to buy promising candidates. 
Via InvestorPlace
News headline image
Wall Street's Most Accurate Analysts Say Hold These 3 Health Care Stocks With Over 3% Dividend Yields ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
 
Via Benzinga
News headline image
Nasdaq 100 Falls To 7-Week Lows, Marks Worst 2-Day Drop In Nearly 2 Years As Tech Rout Rages On ↗
Nasdaq 100 index falls to its lowest level since June amid volatility. Despite a brief boost from Q2 GDP growth and decreasing prices, it dropped 4.7% in 2 sessions. 
Via Benzinga
News headline image
Gilead Sciences to Release Second Quarter 2024 Financial Results on Thursday, August 8, 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
News headline image
3 Stocks That Can Help You to Get Richer in 2024 and Beyond ↗
Good bargains still abound in the market, and two of the stocks below offer fat dividends as well. 
Via The Motley Fool
News headline image
Gilead's $42.5K Priced HIV Drug Could Be Made At Just $40 Annually, Campaigners Urge Company To Slash Price ↗
Gilead Sciences' lenacapavir, marketed as Sunlenca, is under scrutiny for its $42,250 annual price despite research suggesting it could be produced for $40. Campaigners are urging for global price... 
Via Benzinga
News headline image
Full Efficacy and Safety Results for Gilead Investigational Twice-Yearly Lenacapavir for HIV Prevention Presented at AIDS 2024
From Gilead Sciences, Inc.
Via Business Wire
News headline image
Pfizer And GSK's ViiV Healthcare's Two-Drug HIV Treatment Matches Gilead's Three-Drug Combo In Major Trial ↗
ViiV Healthcare's Dovato matches Gilead's Biktarvy in effectiveness for HIV treatment. The study reveals Dovato's benefit of less weight gain compared to Biktarvy, highlighting its efficacy and patient... 
Via Benzinga
News headline image
AnaptysBio Investigational Arthritis Drug Might Have Better Efficacy Profile Than Eli Lilly's: Analyst ↗
HC Wainwright initiated coverage on AnaptysBio with a Buy rating and a $55 price target. AnaptysBio focuses on immunology therapeutics with a promising pipeline. 
Via Benzinga
News headline image
Biotech Bull Market Is Intact But SMIDs Are Too Volatile ↗
It was another wild week for the market as it had to contend with a lot of news. 
Via Talk Markets
< Previous 1 2
...
19 20 21 22 23 24 25 26 27
...
71 72 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.